sapience logo
  • About
    • Overview
    • Management
    • Directors
    • Advisors
  • Approach
    • Overview
    • Spears™
    • PADS™
  • Pipeline
    • Overview
    • ST101
    • ST316
    • cJun Program
    • FoxP3 Program
  • Clinical Trials
    • ST101
    • Expanded Access
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Careers
    • Careers
    • Open Opportunities
  • Contact

Presentations

Presentations

iwamoto_CTNI-49_Early signal of activity from a phase 2 study of ST101, a first-in-class peptide antagonist of CEBPbeta in recurrent glioblastoma (GBM) thumb

November 18, 2022

Early signal of activity from a phase 2 study of ST101, a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ), in recurrent glioblastoma (GBM)

SITC_2022 Final (1) thumb

November 10, 2022

ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responses

Triple meeting poster (203) E_Fontana final thumb

October 27, 2022

Efficacy signals, long-term exposure and safety data from a phase 1-2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients with refractory solid tumors

Sapience ASCO poster - 2022 thumb

June 3, 2022

Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors

2022 ST101 non-clin pkpd Final thuymb

April 11, 2022

Characterizing the PK/PD relationship of C/EBPβ antagonist peptide ST101 in a mouse orthotopic breast cancer model

ST316 Final thumb

April 11, 2022

β-catenin antagonist peptide, ST316, attenuates Wnt-dependent oncogenic activity

Sapience Therpeutics _ESMO 2021 poster thumb

September 16, 2021

Efficacy, safety, pharmacokinetic and pharmacodynamic data from phase 1 dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients with advanced and metastatic solid tumors

Sapience AACR poster 2021 - #964 thumb

April 9, 2021

β-catenin antagonist peptide attenuates Wnt-dependent oncogenic activity

Sapience AACR Poster 2021 - #959 thumb

April 9, 2021

C/EBPβ antagonist peptide, ST101, as a potential therapeutic approach in breast cancer

Sapience Therapeutics - 2020 AACR poster - beta-catenin thumb

June 22, 2020

β-catenin antagonist peptide attenuates oncogenic gene transactivation and promotes antitumor activity in breast cancer models

Sapience Therapeutics - 2020 AACR poster - ST101 thumb

June 22, 2020

C/EBPβ antagonist peptide, ST101, attenuates oncogenic gene transactivation in cancer cells to drive antitumor activity

Cell penetrating peptide, ST101, disrupts ATF5 regulation

April 1, 2019

Cell penetrating peptide, ST101, disrupts ATF5 regulation of anti-apoptotic Bcl-2 family proteins, resulting in induction of cancer cell death in vitro and tumor growth inhibition/regression in vivo

sapeince logo

 ©2023 Sapience Therapeutics, Inc.
All Rights Reserved

Explore

  • About
  • Approach
  • Pipeline
  • Clinical Trials
  • News & Events
  • Careers
  • Contact

Contact

500 Mamaroneck Ave
Suite 320
Harrison, NY 10528

Tel: (914) 607-6930

Follow Us

linkedin logo

Legal

  • Policies
  • Disclaimer
logo
  • About
    • Overview
    • Management
    • Directors
    • Advisors
  • Approach
    • Overview
    • Spears™
    • PADS™
  • Pipeline
    • Overview
    • ST101
    • ST316
    • cJun Program
    • FoxP3 Program
  • Clinical Trials
    • ST101
    • Expanded Access
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Careers
    • Careers
    • Open Opportunities
  • Contact